Prothena Corp Public Ltd Co (PRTA) Stock Price & Analysis
Prothena Corp Public Ltd Co (PRTA) fell 1.05% to USD 8.47 as of June 10, 2026 at 02:14 UTC, according to Nexqual real-time market data.
PRTA last closed at USD 8.56; the session ranged USD 8.35–8.87 on volume of 481,082 shares. Market capitalization is $443.43M, with a 52-week range of USD 4.95–11.8 (NMS). Source: Nexqual, June 10, 2026 at 02:14 UTC.
Key Statistics (as of June 10, 2026 at 02:14 UTC)
| Price | USD 8.47 |
|---|---|
| Change | ▼ 1.05% (down) |
| Previous Close | USD 8.56 |
| Open | USD 8.56 |
| Day Range | USD 8.35 – 8.87 |
| 52-Week Range | USD 4.95 – 11.8 |
| Volume | 481,082 shares |
| Market Cap | $443.43M |
| Exchange | NMS |
Technical Analysis (PRTA)
Nexqual's technical model rates PRTA "SELL" based on 1 bullish and 5 bearish signals across 124 daily candles, as of June 10, 2026 at 02:14 UTC.
| Overall Signal | SELL |
|---|---|
| RSI (14) | 34.16 (neutral) |
| vs SMA50 | Below (USD 10.11) |
| MACD | -0.38 (negative) |
Analyst Ratings (PRTA)
Wall Street analysts rate PRTA "None" based on 5 analysts, with a mean price target of USD 21.4 (range USD 8–36), per Nexqual as of June 10, 2026 at 02:14 UTC.
| Consensus Rating | None |
|---|---|
| Analyst Count | 5 |
| Mean Target | USD 21.4 |
| High Target | USD 36 |
| Low Target | USD 8 |
| Buy / Hold / Sell | 3 / 2 / 1 |
Earnings (PRTA)
| Next Earnings Date | 2026-08-03 |
|---|---|
| EPS Estimate | USD 0.38 |
| Revenue Estimate | $425,830 |
Recent Earnings History
| Quarter | Actual vs Estimate |
|---|---|
| 2026-03-31 | USD 0.68 vs est -0.31 ▲ beat |
| 2025-12-31 | USD -0.46 vs est -0.46 ▲ beat |
| 2025-09-30 | USD -0.67 vs est -0.54 ▼ miss |
| 2025-06-30 | USD -1.73 vs est -1.79 ▲ beat |
Source: Nexqual, June 10, 2026 at 02:14 UTC.
Financials & Fundamentals (PRTA)
| Total Revenue | $57.94M |
|---|---|
| Revenue Growth (YoY) | +1706.40% |
| Gross Margin | -66.84% |
| Operating Margin | +50.49% |
| Profit Margin | -260.92% |
| ROE | -40.30% |
| Debt / Equity | 2.45 |
| Current Ratio | 10.43 |
| Total Cash | $329.46M |
| Total Debt | $7.65M |
| Free Cash Flow | $-31.58M |
Source: Nexqual, June 10, 2026 at 02:14 UTC.
Financial Health Score (PRTA)
Nexqual rates Prothena Corp Public Ltd Co's overall financial health "Weak" across five dimensions, as of June 10, 2026 at 02:14 UTC.
| Growth | Critical — Revenue -93% YoY (annual), sharp decline |
|---|---|
| Profitability | Weak — Pre-revenue or very early stage |
| Balance Sheet | Strong — $329M cash vs $8M debt, net cash position |
| Cash Flow | Weak — FCF negative: -$32M, burning cash |
| Efficiency | Critical — ROE -40%, ROA -13.8% |
Ownership (PRTA)
| Insider Ownership | +20.43% |
|---|---|
| Institutional Ownership | +90.68% |
| Shares Outstanding | 52.35M |
| Float | 36.55M |
| Short % of Float | +17.73% |
Source: Nexqual, June 10, 2026 at 02:14 UTC.
Leadership (PRTA)
Prothena Corp Public Ltd Co is led by Gene G. Kinney (age 56), President, CEO & Director, per Nexqual as of June 10, 2026 at 02:14 UTC.
| President, CEO & Director | Gene G. Kinney (age 56) |
|---|---|
| Chief Financial Officer | Tran B. Nguyen (age 51) |
| Chief Operating Officer | Brandon S. Smith (age 50) |
| Chief Scientific Officer | Wagner M. Zago (age 52) |
| Vice President of Investor Relations | Mark C. Johnson C.F.A. |
Major Backers & Investors (PRTA)
Notable institutional backers of Prothena Corp Public Ltd Co include FMR, LLC, Rubric Capital Management LP, Fidelity, according to Nexqual as of June 10, 2026 at 02:14 UTC.
Active Investors
| Investor | Stake |
|---|---|
| FMR, LLC | 14.42% |
| Rubric Capital Management LP | 9.55% |
| Fidelity | 8.41% |
| Shaw D.E. & Co., Inc. | 3.37% |
| Adar1 Capital Management, LLC | 3.02% |
| Acadian Asset Management. LLC | 2.96% |
| Morgan Stanley | 2.35% |
Index Funds (Passive)
| Fund | Stake |
|---|---|
| BlackRock | 10.88% |
| State Street | 5.75% |
| Vanguard Group | 4.86% |
Source: Nexqual, June 10, 2026 at 02:14 UTC.
From Prothena Corp Public Ltd Co's Latest SEC 10-K Filing (filed 2026-02-27)
Key Strengths & Strategy (as disclosed to the SEC)
- Prothena Corporation plc, a late-stage clinical biotechnology company, focuses on discovery and development of novel therapies to treat diseases caused by protein dysregulation.
- Its product pipeline includes Prasinezumab, an investigational humanized monoclonal antibody which is in Phase 3 clinical trial for the treatment of parkinson's disease and other synucleinopathies.
- The company also develops Coramitug, an investigational antibody, which is in Phase 3 clinical trial for the treatment of transthyretin amyloidosis; BMS-986446, an anti-tau antibody which is in Phase 2 clinical trial to treat Alzheimer's disease; PRX019, an investigational antibody which is in Phase 1 clinical trial for the treatment of neurodegenerative diseases; and PRX123, a Dual Aß-Tau Vaccine, which is in preclinical trial for treating Alzheimer's disease.
- In addition, it develops discovery- and late-preclinical-stage programs include TDP-43 CYTOPE for the treatment of amyotrophic lateral sclerosis; PRX012, a next-generation anti-Aß antibody which is in phase 1 clinical trial to treat Alzheimer's disease; and PRX012-TfR, a preclinical program for the treatment of Alzheimer's disease.
Source: SEC EDGAR 10-K, official filing. Curated by Nexqual.
Peers & Related Stocks
| Symbol | Name | Price | Change |
|---|---|---|---|
| PTCT | PTC Therapeutics, Inc. | USD 73.68 | ▲ 3.82% |
| RARE | Ultragenyx Pharmaceutical Inc. | USD 22.79 | ▲ 4.02% |
| AGIO | Agios Pharmaceuticals, Inc. | USD 28.14 | ▼ 0.53% |
| ENTA | Enanta Pharmaceuticals, Inc. | USD 11.35 | ▲ 0.62% |
| XNCR | Xencor, Inc. | USD 11.89 | ▲ 1.02% |
Data source: Nexqual — real-time market data, technical indicators, analyst consensus, earnings, SEC EDGAR filings. Last updated: June 10, 2026 at 02:14 UTC. This page is informational and not investment advice.